Transplacentar induction of neurogenic malignomas by 1,2-diethyl-hydrazine, azo-, and azoxy-ethane in rats

Pathology and molecular genetics of oligodendroglial tumors

Oligodendroglial gliomas are second only to astrocytic gliomas in frequency. The lack of stringent diagnostic criteria cause high interobserver variation in regard to classification and grading of these tumors. Previous studies have described oligodendrogliomas with features that overlap with those of neurocytic tumors, thus further complicating diagnostic decisions. The increasing need for standardized diagnostic criteria in this subset of gliomas is emphasized by the benefit of adjuvant therapies in patients with anaplastic oligodendrogliomas. Characteristic chromosomal aberrations have been successfully determined for oligodendroglial tumors in recent years. In contrast to astrocytomas, however, no genes in the affected regions have been clearly linked to their pathogenesis. However, the molecular findings promise to be helpful for diagnostic and therapeutic decisions. This review compiles clinical, pathological, and molecular genetic findings on WHO grades II and III oligodendrogliomas and oligoastrocytomas.

Current and future strategies for the treatment of malignant brain tumors

Glioblastoma (GB) is the most common subtype of primary brain tumor in adults. These tumors are highly invasive, very aggressive, and often infiltrate critical neurological areas within the brain. The mean survival time after diagnosis of GB has remained unchanged during the last few decades, in spite of advances in surgical techniques, radiotherapy, and also chemotherapy; patients' survival ranges from 9 to 12 months after initial diagnosis. In the same time frame, with our increasing understanding and knowledge of the physiopathology of several cancers, meaningful advances have been made in the treatment and control of several cancers, such as breast, prostate, and hematopoietic malignancies. Although a number of the genetic lesions present in GB have been elucidated and our understanding of the progressions of this cancer has increased dramatically over the last few years, it has not yet been possible to harness this information towards developing effective cures. In this review, we will focus on the classical ways in which GB is currently being treated, and will introduce a novel therapeutic modality, i.e., gene therapy, which we believe will be used in combination with classical treatment strategies to prolong the life-span of patients and to ultimately be able to control and/or cure these brain tumors. We will discuss the use of several vector systems that are needed to introduce the therapeutic genes within either the tumor mass, if these are not resectable, or the tumor bed, after successful tumor resection. We also discuss different therapeutic modalities that could be exploited using gene therapy, i.e., conditional cytotoxic approach, direct cytotoxicity, immunotherapy, inhibition of angiogenesis, and the use of pro-apoptotic genes. The advantages and disadvantages of each of the current vector systems available to transfer genes into the CNS are also discussed. With the advances in molecular techniques, both towards the elucidation of the physiopathology of GB and the development of novel, more efficient and less toxic vectors to deliver putative therapeutic genes into the CNS, it should be possible to develop new rationale and effective therapeutic approaches to treat this devastating cancer.

Tumors of the nervous system in carcinogenic hazard identification

In the absence of adequate data on humans, it is biologically plausible and prudent to regard agents and mixtures for which there is sufficient evidence of carcinogenicity in experimental animals, usually rats and mice, as if they presented a carcinogenic risk to humans. Prediction of cancer sites in humans from bioassay data in rodents is much less certain, however, regardless of organ or tissue. For tumors of the nervous system, there is practically no basis for judging the validity of such predictions, as only ionizing radiation is known to cause tumors of the central nervous system (CNS) in humans. Brain tumors are relatively uncommon findings in bioassays and are rare in untreated rodents, even in rats, which appear to be the most susceptible species. However, CNS tumors have been readily induced in rodents by systemic exposures to some chemicals, notably N-nitrosoalkylureas and other alkylating agents and certain alkyl hydrazine derivatives. CNS tumors in rodents have played a significant role in carcinogenic hazard evaluations of several other chemicals, including acrylonitrile, ethylene oxide, and acrylamide, and have been implicated as part of the tumor spectrum induced by vinyl chloride and certain inorganic lead compounds. In some of these evaluations, it is not certain that all tumors diagnosed as primary brain tumors were correctly identified. Diagnostic difficulties have been presented by undifferentiated small-cell tumors that may invade the brain, including carcinomas of the nasal cavity and undifferentiated schwannomas arising in cranial nerve ganglia, and by the difficulty of reliably distinguishing between focal reactive gliosis and early glial neoplasms. The most striking experimental finding regarding the induction by chemicals of tumors of the nervous system is the dramatically greater susceptibility of the fetal and neonatal nervous system to some carcinogens, as compared with the susceptibility of the nervous system in adults of the same species.

Genetic and environmental factors in the etiology of human brain tumors

Experimental studies in rodents using chemical carcinogens and viral oncogenes show a high susceptibility to malignant transformation. Analytical epidemiological studies have revealed an increased risk of human brain tumor development in association with certain occupations but, with the exception of therapeutic X-irradiation, attempts to identify a specific exposure or causative environmental agent have so far been unsuccessful. Thus, endogenous mutations and genetic factors may play a more important role. This view is supported by recent studies on the nature of DNA alterations in human brain tumors. More than 70% of p53 mutations observed during glioma progression are G:C-->A:T transitions, predominantly at CpG sites, i.e. likely to be produced by deamination of 5-mcC or related spontaneous mechanisms. No specific mutations or mutational hot spots were found which could be suggestive of environmental carcinogens operative in the etiology of human brain tumors. A similar pattern of mutation is found in colon cancer, sarcomas, and lymphomas, i.e. neoplasms with largely unknown etiology. This is similarly true for p53 germline mutations which again show a strong preference for G:C-->A:T transitions at CpG sites.

Changes in secondary structure of DNA of rat embryos following treatment with 1,2-diethylhydrazine and dimethylnitrosamine in vivo

1,2-Diethylhydrazine (DEH) and dimethylnitrosamine (DMN) are indirect acting carcinogens that require metabolic activation to exert their potency. DEH is a transplacental carcinogen and teratogen in Wistar rats when administered by i.p. injection on day 12 of gestation. DMN is embryotoxic during this period. In this study, gravid Wistar rats were injected i.v. with DEH (10, 15, or 20 mg/kg) or i.p. with DMN (10 or 30 mg/kg) and the effects on the embryos 24 hours later were observed. Controls were similarly injected with saline vehicle. The incidence of resorptions increased after treatment with 20 mg DEH/kg. DEH treatment also resulted in decreases in embryo wet weights and total DNA that were not dose dependent. Treatment with DMN did not affect embryonic wet weights and total embryonic DNA amount when compared to the saline-treated controls. The effects of DEH and DMN on DNA synthesis in vivo were monitored by injecting [methyl-14C]-thymidine 1 hour prior to embryo death. DEH induced significant increases in thymidine incorporation into embryo DNA but the increases were not proportional to the doses administered. DNA synthesis was significantly decreased in embryos treated with 30 mg DMN/kg. The DNA of treated and control embryos was fractionated by benzoylated DEAE-cellulose (BD-cellulose) chromatography to determine differences in DNA secondary structure following treatment. BD-cellulose chromatography separates double-stranded DNA from DNA containing single-stranded regions by step elution with 1 M NaCl solution and caffeine solution, respectively. Embryonic DNA was monitored by in vivo labelling with [methyl-3H]-thymidine on days 6 and 7 of gestation. Significant dose dependent increases in percentages of caffeine-eluted DNA (%CE-DNA) compared to controls were detected after treatment with 10, 15, and 20 mg DEH/kg and 10 and 30 mg DMN/kg. The relative %CE-DNA is expressed as the ratio of %CE-14C-labeled DNA to %CE-3H-labeled DNA. Litters treated with 10, 15, and 20 mg DEH/kg had relative %CE-DNA values significantly lower than controls. The results support the hypothesis that initiation mechanisms of transplacental carcinogenesis and teratogenesis are different. The pertinence of %CE-DNA and relative %CE-DNA values to the study of transplacental carcinogenesis and teratogenesis is discussed.

Carcinogenesis induced by a single administration of 1,2-diethylhydrazine in female rats of various ages

Three- or fourteen-month-old female L10 rats were exposed to a single intravenous injection of 1,2-diethylhydrazine (SDEH) at 150 mg/kg of body weight. At the 95th week after carcinogen treatment when the experiment was stopped, 30.7% and 4.5% of rats from the younger and older groups survived, respectively. Total tumor incidences were 68.8% and 84.6%, respectively, in rats treated with SDEH at the age of 3 or 14 months vs. 18.2% and 34.5% in corresponding young and old controls (P < 0.01). Leukemias, thyroid adenomas, uterine tumors and mammary malignancies developed more frequently in animals exposed to carcinogens than in control groups. No age-related differences in tumor incidence or localization between rats exposed to SDEH at various ages were observed, but tumors developed earlier in older groups than in younger groups. The results supported the suggestion that the accumulation of initiated cells in some tissues during natural aging is a cause of the age-related increase in cancer incidence.

Occurrence of glioblastoma multiforme in three closely related patients

Three cases of glioblastoma multiforme are presented. These cases have in common the fact that all three patients were relatives but not blood relatives. There had been prolonged intimate contact between them before the development of the neoplastic lesion.

Transplacental carcinogenesis with radioactive phosphorus

1 An attempt was made to produce a model of osteogenic sarcoma using 32P transplacentally. 2 Fetal tissues appeared to be resistant to irradiation as no tumour was induced at an increased frequency in treated animals. 3 Tumours that normally occur in our strain (Sprague-Dawley rats) showed a clear tendancy to occur earlier in post-natal life in treated animals compared with controls.

Medulloblastomas and other neural tumours in mice treated neonatally with N-ethyl-N-nitrosourea

Newborn mice of four inbred strains were injected with a single dose of N-ethyl-N-nitrosourea. The wide range of tumours induced included a small number in the central and peripheral nervous systems. The 4 brain tumours all arose in the cerebellum. Three in one strain were medulloblastomas showing continuity with the internal granular layer. All three tumours showed diffuse infiltration through the molecular layer and continuity with densely-packed islets of cells that marginated immediately beneath the pia and closely resembled remnants of a persistent fetal external granular layer. The medulloblastomas are discussed with special relevance to the histogenesis of the equivalent tumour in man.

Transplacental induction of lymphomas in Swiss mice by carbendazim and sodium nitrite

Swiss mice at different stages of pregnancy were treated intragastrically with the pesticide Carbendazim (MBC, BCM, methyl-2-benzimidazole carbamate) together with sodium nitrite. Lymphomas developed in 33.3% of young mice whose mothers were treated in the first week of pregnancy, in 53.3% of whose mothers were treated during the second week, and in 38.8% of those born of mothers treated during the third week. Treatment during the whole period of pregnancy yielded on an average 70.0% malignancy in offspring. However, administration of Carbendazim by itself did not produce lymphomas in the first generation. In lymphomas induced by in vivo-formed n-nitroso compounds, A- and C-type oncornavirus particles were observed with the electron microscope.

Morphological studies of rat brain tumors induced by N-nitrosomethylurea

✓ Experimental glial tumors were induced by weekly intravenous injections of N-nitrosomethylurea (NNMU) in rats. The tumors included low- and high-grade gliomas of the astrocytic series and mixed gliomas. The histology of the tumors did not vary significantly with serial passage through tissue culture, subcutaneous implantation, or freezing. These neoplasms provide reliable animal models of brain tumors common to man.